February 20, 2018 / 1:21 PM / 3 months ago

BRIEF-Soleno Therapeutics Announces Successful End-Of-Phase II Meeting With FDA For DCCR In Prader-Willi Syndrome

Feb 20 (Reuters) - Soleno Therapeutics Inc:

* SOLENO THERAPEUTICS ANNOUNCES SUCCESSFUL END-OF-PHASE II MEETING WITH FDA FOR DCCR IN PRADER-WILLI SYNDROME

* SOLENO THERAPEUTICS INC - ‍MINUTES OF MEETING CONFIRMED FDA, CO ALIGNED ON ALL KEY ASPECTS OF CO’S PLANNED PHASE III CLINICAL TRIAL FOR DCCR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below